Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar + sintilimab + platinum-doublet first-line trial in advanced driver-negative NSCLC
ChiCTR2100053353Phase 4Not yet recruiting
- Sponsor
- Zigong First People's Hospital
- Start
- Sep 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of endostar and sintilimab in non-small cell lung cancer (NSCLC), sponsored by Zigong First People's Hospital. Primary endpoint: Tumor size. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
endostarsintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100053353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053353.